Lab-grown human tissue testing services and drug-testing workflow software sold to drug companies and biotech labs.
Organoid and AI-enabled biotech tooling for drug testing
Regulatory and market pressure to move away from animal testing, plus the AI spotlight in biotech, make scalable lab-grown human tissues and workflow software worth a closer look. Intero Biosystems is pushing mini human intestines as alternatives to animal tests, and Colossal Biosciences’ new AI platform underscores AI’s role in accelerating complex biotech programs for pharma.
Projected Score
as a side gig ☆☆☆☆☆ (0/5)
no money or audience ★☆☆☆☆ (1/5)
with both ★★★☆☆ (3/5)
Want this one researched? Commission the full dossier for $15: we research and write it, and you read it first. Then you choose — pay more to keep it exclusive, or do nothing and it goes public on this site. The score above is our forecast for a dossier we haven’t written yet.
The news behind it
- Oct 15, 2026 TechCrunch: Intero Biosystems wants drugmakers to test on mini human intestines, not animals
- Oct 15, 2026 TechCrunch: Colossal Biosciences announces new AI platform to help accelerate de-extinction efforts
